New combo therapy for lung cancer shows promise in early trial
NCT ID NCT03916419
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new treatment approach for people with inoperable non-small cell lung cancer. It combined MRI-guided radiation therapy with chemotherapy and an immunotherapy drug called durvalumab. The goal was to see if this combination is safe and effective at controlling the cancer. The trial enrolled 26 participants and focused on reducing side effects and improving local tumor control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Durvalumab (Imfinzi) plus chemotherapy (paclitaxel and carboplatin) and radiation therapy
What this could lead to
If successful, this approach could offer a more precise and effective treatment for inoperable lung cancer, potentially improving local tumor control and survival.
What could go wrong
This is a small, single-arm phase 2 trial, so results may not apply to all patients. There are risks of side effects from radiation, chemotherapy, and immunotherapy, including lung inflammation and other toxicities.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIA NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States